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Abstract
Objective—We propose a new staging system for stage I endometrial cancer and compare its 
performance to the 1988 and 2009 International Federation of Gynecology and Obstetrics (FIGO) 
systems.
Methods—We analyzed patients with 1988 FIGO stage I endometrial cancer from January 1993 
to August 2011. Low-grade carcinoma consisted of endometrioid grade 1 to grade 2 lesions. High-
grade carcinoma consisted of endometrioid grade 3 or nonendometrioid carcinomas (serous, clear 
cell, and carcinosarcoma). The proposed system is as follows:
IA Low-grade carcinoma with less than half myometrial invasion
IA1 Negative nodes
IA2 No nodes removed
IB High-grade carcinoma with no myometrial invasion
IB1 Negative nodes
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IB2 No nodes removed
IC Low-grade carcinoma with half or greater myometrial invasion
IC1 Negative nodes
IC2 No nodes removed
ID High-grade carcinoma with any myometrial invasion
ID1 Negative nodes
ID2 No nodes removed
Results—Data from 1843 patients were analyzed. When patients were restaged with our 
proposed system, the 5-year overall survival significantly differed (P < 0.001): IA1, 96.7%; IA2, 
92.2%; IB1, 92.2%; IB2, 76.4%; IC1, 83.9%; IC2, 78.6%; ID1, 81.1%; and ID2, 68.8%. The 
bootstrap-corrected concordance probability estimate for the proposed system was 0.627 (95% 
confidence interval, 0.590–0.664) and was superior to the concordance probability estimate of 
0.530 (95% confidence interval, 0.516–0.544) for the 2009 FIGO system.
Conclusions—By incorporating histological subtype, grade, myometrial invasion, and whether 
lymph nodes were removed, our proposed system for stage I endometrial cancer has a superior 
predictive ability over the 2009 FIGO staging system and provides a novel binary grading system 
(low-grade including endometrioid grade 1–2 lesions; high-grade carcinoma consisting of 
endometrioid grade 3 carcinomas and nonendometrioid carcinomas).
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INTRODUCTION
Endometrial cancer is the most common gynecologic malignancy in the United States, with 
the disease diagnosed in an estimated 47,000 women in 2012. Because most women had 
their diagnosis at an early stage, only approximately 8000 women died of their disease in 
2012.1 The International Federation of Gynecology and Obstetrics (FIGO) endometrial 
cancer staging system was changed from a clinical to a surgical staging system in 1988 
based on large clinicopathologic studies highlighting the importance of pathologic 
findings.2,3 The 1988 FIGO system for stage I endometrial cancer had 3 subgroups: IA, no 
myometrial invasion; IB, less than half myometrial invasion; and IC, half or greater 
myometrial invasion. The revised, 2009 FIGO system combined stages IA and IB, resulting 
in 2 subgroups: IA, no or less than half myometrial invasion; and IB, half or greater 
myometrial invasion.4
Most patients with endometrial cancer have stage I disease at diagnosis, but this is not a 
homogeneous population. Many of these women will be cured of their disease, but some 
will recur and may die of their disease. Both the 1988 and 2009 FIGO staging systems for 
stage I endometrial cancer are based solely on myometrial invasion. A recent publication by 
The Cancer Genome Atlas Research Network on endometrial carcinoma highlighted the 
importance of tumortyping in overall survival prognosis.5 The authors found 4 endometrial 
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cancer types: DNA polymerase epsilon (POLE) ultramutated, microsatellite instability 
hypermutated, copy number low, and copy number high. The copy number high group 
(serous-like), which was composed of mostly serous tumors and grade 3 endometrioid 
tumors, had the worst prognosis.
This prognostic histologic information can be incorporated into a revisedstaging system. In 
addition, previous FIGO staging systems for stage I endometrial cancer do not take into 
account whether or not lymph nodes were removed, which continues to be a controversial 
area in endometrial cancer surgical staging. Moreover, the grading system remains 
unchanged, with 3 grade categories.
Accommodating for the distinctive characteristics of different disease types (histological 
subtypes) is not novel. International Federation of Gynecology and Obstetrics 2009 
recognizes the distinctive characteristics of gynecologic histologic subtypes, providing 
different staging schemes for uterine carcinoma and carcinosarcoma than for uterine 
leiomyosarcoma, endometrial stromal sarcoma, and Mullerian adenosarcoma. Our data show 
that incorporating histological subtype and whether or not lymph nodes were removed 
(“nodes known” vs “nodes unknown”) improves prognostic accuracy for patients with FIGO 
stage I endometrial carcinoma.
The purpose of this study was to develop a new staging system for stage I endometrial 
cancer that, in addition to myometrial invasion, takes into consideration disease type (ie, 
histological subtype), grade (using a binary system instead of a 3-grade system), and 
whether or not lymph nodes were examined. Such a staging system for stage I endometrial 
cancers would reflect the current reality of surgical staging of this disease, given the 
controversy over the role of lymphadenectomy in endometrial cancer staging. We aimed to 
compare the performance of the new system to the 1988 and 2009 FIGO staging systems.
MATERIALS AND METHODS
With the approval of the institutional review board of Memorial Sloan Kettering Cancer 
Center, all patients who underwent surgery and had a diagnosis of 1988 FIGO stage I 
endometrial cancer from January 1993 through August 2011 were analyzed. Sarcomas and 
undifferentiated carcinomas were excluded. Twelve patients had mixed tumor types, and 14 
patients had mucinous histology. After review by our expert gynecologic pathologists, it was 
decided that these would best be analyzed as part of the endometrioid histologic subtype. 
Standard demographic, clinical, and pathologic data were extracted. We defined 
endometrioid grade 1 or 2 cancers as “low grade”, and we defined endometrioid grade 3 or 
nonendometrioid carcinomas (serous, clear cell, and carcinosarcoma) as “high grade”. We 
proposed the following substaging definitions for stage I endometrial cancers:
IA Low-grade carcinoma with less than half myometrial invasion
IA1 Negative nodes
IA2 No nodes removed
IB High-grade carcinoma with no myometrial invasion
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IB2 No nodes removed
IC Low-grade carcinoma with half or greater myometrial invasion
IC1 Negative nodes
IC2 No nodes removed
ID High-grade carcinoma with any myometrial invasion
ID1 Negative nodes
ID2 No nodes removed
The vital status of each patient was recorded. Overall survival (OS) was calculated from the 
date of surgery to either date of last follow-up or death. The Kaplan-Meier method was used 
to estimate OS probabilities. Univariate OS analysis was performed using the log-rank test, 
and the Cox proportional hazards model was fitted univariately to estimate the hazard ratio 
for each covariate separately.
We compared the 1988, 2009, and our proposed endometrial cancer stage I system using the 
concordance probability, which is a measure of predictive accuracy.6 Analogous to area 
under the receiver operating curve, concordance probability estimate (CPE) can range from 
perfect concordance at 1.0 to perfect discordance at 0.0. More specifically, a CPE of 50% 
implies no predictive accuracy because for 2 randomly selected patients, there is a 50% 
chance that the patient with the higher predicted probability by the staging system will have 
longer survival than the other patient, which is no better than a coin flip. To prevent against 
overfitting the model, the bootstrap-corrected CPE was also reported.7
RESULTS
A total of 1843 women met study criteria and were analyzed. Demographic information is 
summarized in Table 1. More than 80% of the patients were alive without evidence of 
disease at last follow-up. Among the 1592 survivors, the median follow-up time was 49.7 
months. The median age was 61 years, and the median body mass index was 29.9 kg/m2.
Eighty-seven percent of the women had endometrioid carcinoma; and the remainder had 
serous carcinoma, carcinosarcoma (malignant mixed Mullerian tumors), or clear cell 
carcinoma. During the study period, 67.8% of the patients had lymph nodes removed. 
Among the 1249 patients with lymph nodes excised, the median lymph node count was 16. 
The median number of pelvic and para-aortic lymph nodes removed was 13 and 3, 
respectively.
On univariate analysis, age, grade, disease type (ie, histological subtype), and staging using 
the 1988, the 2009, and the new proposed staging systems were all significantly associated 
with OS (Table 2). The removal of lymph nodes was not statistically significant (P = 0.103). 
The 5-year OS rates for the 1988 staging system were the following: IA, 95.4%; IB, 88.4%; 
and IC, 81.1% (P < 0.001). The Kaplan-Meier OS curves stratified by the 1988 FIGO stage I 
system are shown in Figure 1A. The 5-year OS rates for the 2009 staging system were IA, 
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91.5%; and IB, 81.1% (P < 0.001), as illustrated in Figure 1B. When patients were restaged 
with our proposed system for stage I disease, the 5-year OS rates significantly differed (P < 
0.001) as follows: IA1, 96.7%; IA2, 92.2%; IB1, 92.2%; IB2, 76.4%; IC1, 83.9%; IC2, 
78.6%; ID1, 81.1%; and ID2, 68.8%. The Kaplan-Meier analysis for the proposed new 
system is presented in Figure 2.
A cross-tabulation of the 1988, the 2009, and the proposed endometrial cancer stage I 
systems is shown in Table 3. Most patients had no or less than 50% myometrial invasion and 
had grade 1 or 2 endometrioid adenocarcinoma. Thirteen percent (239/1843) of the patients 
who would otherwise have been classified as stage IA using the 2009 system were classified 
as stage ID using the proposed system.
DISCUSSION
The Proposed Staging System Is More Prognostically Powerful Than Existing and 
Previous Systems
Gynecologic cancer stage definitions are designed to provide relevant clinical information, 
inform prognosis, and assist in guiding patient management decisions.8 It has been stated 
that a good staging system must have 3 basic characteristics: it must be valid, reliable, and 
practical.9 It should group patients who experience similar outcomes together, ensure that 
identical cases are always assigned to the same category, and should reflect clinical practice. 
Because endometrial cancer often presents with postmenopausal or irregular vaginal 
bleeding, most women are diagnosed at an early stage. However, patients with early-stage 
endometrial cancer comprise a heterogeneous population with regard to histologic subtype, 
tumor grade, and prognosis. A stage I definition that divides this group into 2 groups based 
solely on myometrial invasion, as with the 2009 FIGO stage I system, is inadequate for 
providing accurate prognostic information. Additional relevant clinical information should 
be incorporated to place patients in the appropriate prognostic group and manage them 
appropriately. We propose a staging system for stage I endometrial cancer that goes beyond 
myometrial invasion and incorporates disease type (ie, histological subtype), grade (a binary 
system of low versus high grade), and whether or not lymph nodes were evaluated.
The FIGO staging system for endometrial cancer has undergone several revisions through 
the years based on emerging information, but these changes have not always improved the 
performance of the staging system. Specific to stage I disease, our group questioned whether 
the 1988 FIGO stages IA and IB should have been altered.10 Using data from more than 
1600 women, the OS of women with stage I endometrial cancer was analyzed to evaluate 
the performance of the 1988 and 2009 FIGO staging systems for stage I endometrial cancer. 
Both systems provided statistically significant survival differences between substages, but 
the adjusted concordance probability for the 1988 stage I group was 0.612 compared to 
0.536 for the 2009 stage I group. The authors concluded that the revised 2009 system 
eliminated the most favorable group with no myometrial invasion and did not improve its 
predictive ability over the 1988 system, emphasizing the importance of individualized risk 
prediction models.
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The landmark article by Creasman et al. describing the surgical pathologic spread patterns of 
endometrial cancer confirmed previous findings2,11 and laid the groundwork for the change 
in endometrial cancer staging from a clinical to a surgical staging system; they reported that 
the depth of myometrial invasion was an important predictor of extrauterine disease.3 
Myometrial invasion was divided into 4 groups: endometrium only, inner third, middle third, 
and deep third. Invasion was significantly associated with frequency of nodal metastasis. 
The 1988 and 2009 FIGO stage I systems are based solely on depth of myometrial invasion, 
which is an overly simplified division of patients with stage I endometrial cancer.
Grade was another significant risk factor for nodal metastasis in the article by Creasman et 
al and continues to commonly be referred to in combination with depth of myometrial 
invasion to describe the frequency of pelvic and para-aortic node metastases.3 For instance, 
no patients with tumor limited to the endometrium and grade 1 histology had positive pelvic 
or para-aortic nodes, whereas patients with deep myometrial invasion and grade 3 histology 
had a 34% risk of pelvic node metastasis and a 23% risk of para-aortic node metastasis. 
Clearly, grade and depth of invasion are critical pieces of information in determining 
prognosis and management, and our proposed stage I endometrial cancer system takes both 
grade and myometrial invasion into consideration. It further simplifies the grading process 
into a binary system (low vs high grade).
Disease Type Should Be Accounted for in an Endometrial Cancer Staging System Authors 
have argued that the 2009 FIGO staging system for use in uterine serous carcinoma is 
oversimplified.16 Seward et al17 evaluated the prognostic ability of the revised 2009 staging 
system compared to the 1988 system in uterine serous carcinoma and concluded that the 
2009 criteria did not adequately delineate survival for uterine serous carcinoma in early-
stage disease. The patients with no myometrial invasion had the most favorable prognosis, 
which the authors argued warranted a separate substage. Distinguishing serous and low-
grade endometrioid carcinomas without myometrial invasion in a staging scheme allows for 
the discrimination of patients with favorable and potentially highly unfavorable clinical 
outcomes. Unlike low-grade endometrioid carcinomas without myometrial invasion, serous 
carcinomas lacking myometrial invasion are frequently metastatic at presentation, and 
suboptimal staging strategies might fail to recognize patients at highest risk of distant, 
particularly peritoneal, failure. Once low stage is verified after a comprehensive staging 
surgery, our proposal allows for the separation of serous carcinomas into 2 groups stratified 
by the presence of myometrial invasion, thereby preserving the best prognostic group.
Reports that compare clinical outcomes in FIGO grade 3 endometrioid and serous 
carcinomas do not uniformly conclude that these tumor types are comparable, but there are 
several noteworthy studies that describe similar clinical outcomes. During a study period 
using contemporary therapeutic interventions for high-risk endometrial carcinoma, Ayeni et 
al18 controlled for disease stage and reported no difference in OS when comparing grade 3 
endometrioid, serous, and clear cell carcinomas. Another recent publication by Voss et al 
similarly found that disease-specific and recurrence-free survivals were similar between 
grade 3 endometrioid endometrial cancer and serous cancer or clear cell cancer. Previous 
reports have also demonstrated similar clinical outcomes when comparing patients with 
grade 3 endometrioid endometrial carcinoma to women with uterine serous or clear cell 
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histology.19,20 Our proposed stage I endometrial cancer system recognizes the similar 
clinical behavior of grade 3 endometrioid endometrial cancer and the type 2 cancers and 
therefore combines grade 3 endometrioid carcinoma with nonendometrioid carcinoma, 
which in this study included serous, clear cell, and malignant mixed Mullerian tumors.
Furthermore, recent data from The Cancer Genome Atlas Research Network’s study of 
endometrial carcinoma indicate significant genotypic overlap between FIGO grade 3 
endometrioid and serous carcinomas, using historical criteria for diagnosis.5 This work has 
also provided outcomes data that emphasize the distinctive and aggressive nature of serous 
carcinomas and related tumors that mapped to the copy number high cluster. This cluster 
included 94% of serous tumors, 62% of mixed-histology tumors, and 24% of grade 3 
endometrioid tumors. Our staging system provisionally combines grade 3 endometrioid 
carcinoma with nonendometrioid carcinoma while we await the development of precise, 
clinically validated histological criteria that separate the most clinically aggressive tumor 
types (serous carcinoma, carcinosarcoma, and serous-like endometrioid carcinoma) from 
otherwise intermediate-risk carcinomas, such as prototypical FIGO grade 3 endometrioid 
carcinoma.
CONCLUSION
By incorporating the well-recognized and important variables of disease type, grade, 
myometrial invasion, and whether or not lymph nodes were removed (a measure of surgical 
staging), our proposed staging system for stage I endometrial cancer has a superior 
predictive ability over the 2009 FIGO staging system and provides additional relevant 
clinical information over both the 1988 and 2009 systems. In the era of personalized 
medicine, it logically follows that we should use more of the information available to us to 
guide and individualize care for the heterogeneous population of women who have early-
stage endometrial cancer. Adopting this new staging system would provide more accurate 
prognostic information and may assist in treatment planning. The new system also more 
accurately reflects the reality of surgical staging in which patients may not have any nodes 
pathologically assessed. The proposed staging system is not meant to be comprehensive or 
definitive but rather emphasizes the continuous need to revise the existing staging system as 
more is discovered about endometrial carcinoma. The proposed groupings are preliminary 
and could be reformulated for ease of use. Further work is needed to externally validate the 
proposed staging system.
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A, Kaplan-Meier OS analysis stratified by the 1988 FIGO stage 1 system (P < 0.001). B, 
Kaplan-Meier OS analysis stratified by the 2009 FIGO stage 1 system (P < 0.001).
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Kaplan-Meier OS analysis using the newly proposed staging system for stage I endometrial 
cancer without subgroups (P < 0.001).
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Table 1
Patients’ Demographics.
Variable No. Patients Percent
All patients 1843
Vital status
 NED 1547 83.9
 AWD 45 2.4
 DOD 98 5.3
 DOO 114 6.2
 DUN 39 2.1
Age at diagnosis
 Median (mean) 61 (61.3)
 Range 25–96
Weight at diagnosis (71 missing)
 Median (mean) 76.2 (81.1)
 Range 37.0–208.6
Height at diagnosis (117 missing)
 Median (mean) 160 (160.0)
 Range 102.5–186.0
BMI (131 missing)
 Median (mean) 29.9 (31.6)
 Range 13.7–84.1
Uterine weight (579 missing)
 Median (mean) 115 (155.8)
 Range 15–1960
Final grade
 G1 981 53.2
 G2 448 24.3
 G3 414 22.5
Myometrial invasion
 None 819 44.4
 <50% 833 45.2
 ≥50% 191 10.4
Lymphovascular invasion
 No 1177 63.9
 Yes 231 12.5
 Missing 435 23.6
Histologic subtype
 Endometrioid 1602 86.9
 MMMT 72 3.9
 Clear cell 38 2.1
 Serous 131 7.1
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Variable No. Patients Percent
1988 stage
 IA 849 46.1
 IB 804 43.6
 IC 190 10.3
2009 stage
 IA 1653 89.7
 IB 190 10.3
New stage
 IA1 795 43.1
 IA2 473 25.7
 IB1 117 6.4
 IB2 29 1.6
 IC1 95 5.2
 IC2 31 1.7
 ID1 242 13.1
 ID2 61 3.3
Washings
 Negative 1284 69.7
 Positive 4 0.2
 Suspicious 15 0.8
 Missing 540 29.3
Node taken
 None 594 32.2
 Yes 1249 67.8
 Among the 1249 patients with nodes taken
 Total lymph nodes
  Median (mean) 16 (17.8)
  Range 1–71
 Total pelvic lymph nodes
  Median (mean) 13 (14.1)
  Range 0–53
 Total aortic lymph nodes
  Median (mean) 3 (3.8)
  Range 0–26
AWD, Alive with disease; BMI, body mass index; DOD, dead of disease; DOO, dead of other; DUN, dead of unknown reason; MMMT, malignant 
mixed Mullerian tumor; NED, no evidence of disease.
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Table 4
Concordance probability estimate (CPE) values
Bootstrap-Corrected CPE 95% Confidence Interval
1988 stage I 0.615 0.582–0.648
2009 stage I 0.530 0.516–0.544
New stage I* 0.627 0.590–0.664
*
The reported CPE for the new staging system is using all 8 categories of stage I.
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